Keeping Track: FDA Nixes Medicure’s Aggrastat For STEMI, Approves Insys’ Syndros
Executive Summary
The latest drug development news and highlights from our FDA Performance Tracker
You may also be interested in...
Keeping Track: Clarus, Agile and Sunovion Look To Bounce Back From CRLs; FDA To Review Rituximab Biosimilar
The latest drug development news and highlights from our US FDA Performance Tracker.
VC Roundup: Cleave Raises $37m To Maintain Phase I Momentum, Plus $233.5m In Recent Financings
Cleave Biosciences leads off a recent slate of venture capital financings with $37m to fund ongoing Phase I programs for the lead drug from its protein homeostasis-focused platform.
C.Diff Unmet Need Overcomes Bezlotoxumab Panel's Efficacy Concerns
Advisory committee votes 10-5 for approval of the monoclonal antibody for prevention of C. difficile recurrence; drug shows 10% absolute reduction in recurrence vs. placebo.